The eyes in diabetes and diabetes through the eyes

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F07%3A%230000741" target="_blank" >RIV/00064190:_____/07:#0000741 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.diabres.2007.09.023" target="_blank" >http://dx.doi.org/10.1016/j.diabres.2007.09.023</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.diabres.2007.09.023" target="_blank" >10.1016/j.diabres.2007.09.023</a>

Result language
angličtina
Original language name
The eyes in diabetes and diabetes through the eyes
Original language description
Diabetic retinopathy (DR) is the most common of the microvascular complications of diabetes. Left unchecked and untreated, it could progresses from a non-proliferative phase to a proliferative, sight-threatening phase. Macular edema which also threatenssight can appear at any stage. The pathophysiological mechanisms underlying its appearance and progression include the accumulation of plyols, advanced glycation endproducts (AGE) reactive oxygen species, release of local growth factors and activation ofprotein kinase C, all of which lead to structural and functional changes in the retina which can progress to threaten sight. Tight glucose and blood pressure control can prevent the appearance and progression of retinopathy. Novel PKC inhibitors, inhibitors of growth factors, blockers of the renin-angiotensin system (RAS) as well as statins can slow the progression of DR and protect sight.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—

Publication year
2007
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)